Joshua Cohen (L) and Justin Klee, Amylyx co-CEOs
Updated: After long and winding road, FDA approves Amylyx's ALS drug in victory for patients and advocacy groups
For just the third time in its 116-year history, the FDA has approved a new treatment for Lou Gehrig’s disease, or ALS.
US regulators gave …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
